Calithera Biosciences, Inc.
343 Oyster Point Blvd
Suite 200
South San Francisco
California
94080
United States
Website: http://www.calithera.com/
Email: info@Calithera.com
161 articles with Calithera Biosciences, Inc.
-
Calithera to Present at the H.C. Wainwright Global Investment Conference
5/17/2022
Calithera Biosciences, Inc. announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the H.C. Wainwright Global Investment Conference, being held May 23-25 both virtually and in Miami, FL.
-
Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
5/10/2022
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the first quarter ended March 31, 2022.
-
Calithera Biosciences to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
5/3/2022
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company’s first quarter 2022 financial results will be released on Tuesday, May 10, 2022.
-
Calithera Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
3/31/2022
Calithera Biosciences, Inc., a clinical-stage, precision-oncology biopharmaceutical company, announced its financial results for the fourth quarter and year ended December 31, 2021.
-
Calithera Biosciences, Inc. Prices $10.0 Million Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock
3/30/2022
Calithera Biosciences, Inc., a clinical-stage, precision oncology biopharmaceutical company, announced the pricing of its previously announced underwritten public offering of 18,518,519 shares of its common stock at a price to the public of $0.54 per share.
-
Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock
3/29/2022
Calithera Biosciences, Inc., a clinical-stage, precision oncology biopharmaceutical company, announced that it intends to offer and sell shares of its common stock, warrants to purchase shares of its common stock, and pre-funded warrants in an underwritten public offering.
-
Calithera Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 31, 2022
3/24/2022
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company’s fourth quarter and full year 2021 financial results will be released on Thursday, March 31, 2022.
-
Calithera to Present Data Highlighting Newly Discovered Synthetic Lethal Target VPS4 at AACR 2022 Annual Meeting
3/8/2022
Calithera Biosciences, Inc., a clinical-stage, precision oncology biopharmaceutical company, announced that it will present the first data from its preclinical synthetic lethality pipeline at the American Association for Cancer Research 2022 Annual Meeting, being held April 8-13, 2022, in New Orleans, LA.
-
Calithera to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
2/16/2022
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17 at 4:20 p.m. Eastern Time.
-
Calithera to Present at the H.C. Wainwright BioConnect Virtual Conference
1/5/2022
Calithera Biosciences, Inc., a clinical-stage, precision oncology biopharmaceutical company, announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the H.C. Wainwright BioConnect Virtual Conference.
-
Calithera to Present at the 2021 Jefferies London Healthcare Conference
11/12/2021
Calithera Biosciences, Inc., a clinical-stage, precision oncology biopharmaceutical company, announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the 2021 Jefferies London Healthcare Conference.
-
Calithera Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights
11/9/2021
Calithera Biosciences, Inc., a clinical-stage, precision oncology biopharmaceutical company, announced its financial results for the third quarter ended September 30, 2021.
-
Clinical Catch-Up: November 1-5
11/8/2021
The first week of November was marked by numerous clinical trial announcements. Here’s a look. -
Calithera Biosciences Promotes Emil T. Kuriakose, MD, to Chief Medical Officer-- Dr. Kuriakose to succeed Keith Orford, MD, PhD, who will assume seat on Calithera Board of Directors
11/5/2021
Calithera Biosciences, Inc. today announces the promotion of current vice president and head of clinical development, Dr. Emil T. Kuriakose, to chief medical officer (CMO).
-
Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial
11/5/2021
Calithera Biosciences, Inc. announced today the decision to terminate its phase 2 KEAPSAKE clinical trial based on a lack of clinical benefit observed in patients treated with telaglenastat in an interim analysis.
-
Calithera Biosciences to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021
11/2/2021
Calithera Biosciences, Inc., a clinical-stage, precision oncology biopharmaceutical company, announced that the Company’s third quarter 2021 financial results will be released on Tuesday, November 9, 2021.
-
Calithera Presents Interim Data from Phase 1b Trial of Arginase Inhibitor CB-280 in Cystic Fibrosis at NACFC 2021
11/1/2021
Calithera Biosciences, Inc. today shared interim safety and efficacy results from a Phase 1b, randomized, double-blind, placebo-controlled, dose-escalation trial evaluating CB-280, the company’s investigational arginase inhibitor, in adults with cystic fibrosis (CF).
-
The deal was struck one month after GammaDelta dosed its first patient in a Phase I acute myeloid leukemia (AML) trial.
-
Calithera Biosciences to Present First Clinical Data from Development Program for Arginase Inhibitor CB-280 at NACFC 2021
10/21/2021
Calithera Biosciences, Inc. today announced that data from its Phase 1b trial of CB-280, the company’s investigational arginase inhibitor for the treatment of cystic fibrosis (CF), will be shared in a poster presentation at the North American Cystic Fibrosis Conference (NACFC), taking place virtually November 2-5, 2021.
-
Calithera Biosciences is expanding its oncology portfolio with the addition of two clinical-stage compounds from Takeda Pharmaceuticals.